Evidence map›Paper›PMID 29016917›Full record

ReviewPain medicine (Malden, Mass.)2019

Cannabis for the Treatment of Chronic Pain in the Era of an Opioid Epidemic: A Symposium-Based Review of Sociomedical Science.

Dermot P Maher, Daniel B Carr, Kevin Hill, Brian McGeeney, Valerie Weed, William C Jackson, David J DiBenedetto, Edward M Moriarty, Ronald J Kulich

Open access · greenAbstract readReview
In one paragraph

Review in Pain medicine (Malden, Mass.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. The endocannabinoid system and breathing.Frontiers in neuroscience · 2023
    Review
  4. Article
  5. Review
  6. Cannabis for Chronic Pain: Not Ready for Prime Time.American journal of public health · 2019
    Article
  7. Article
  8. Article
  9. Emerging Evidence for Cannabis' Role in Opioid Use Disorder.Cannabis and cannabinoid research · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Dermot P MaherMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Daniel B CarrTufts University School of Dental Medicine, Boston, Massachusetts.
Kevin HillMcLean Hospital, Harvard Medical School, Boston, Massachusetts.
Brian McGeeneyBoston University School of Medicine, Boston, Massachusetts.
Valerie WeedBoston PainCare Center, Boston, Massachusetts.
William C JacksonMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
David J DiBenedettoBoston PainCare Center, Boston, Massachusetts.
Edward M MoriartyMoriarty, Shay and Associates, Wakefield, Massachusetts, USA.
Ronald J KulichMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Harvard University · USCenter for Pain and the Brain · USTufts University · USBoston University · US

Funding

Program in Postdoctoral Research Training in AnesthesiologyT32GM075774 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI SAPNA R KUDCHADKAR, Emmett E Whitaker · 2006 to 2026
$8.1M
Nabilone for Cannabis Dependence: Imaging and Neuropsychological PerformanceR00DA029115 · NIDA · MCLEAN HOSPITAL · PI HILL, KEVIN P. · 2013 to 2015
$819k
Nabilone for Cannabis Dependence: Imaging and Neuropsychological PerformanceK99DA029115 · NIDA · MCLEAN HOSPITAL · PI HILL, KEVIN P. · 2011 to 2012
$359k
NIDA NIH HHS K99 DA029115NIDA NIH HHS R00 DA029115NIGMS NIH HHS T32 GM075774
6 · The paper itself

Abstract

objectiveThis manuscript reviews medical literature published pertaining to the management of chronic pain with medical marijuana therapy (MMJ), with an emphasis on the social, medical, and legal aspects of therapy.

designNarrative review of peer-reviewed literature.

methodsThe 3rd Symposium on Controlled Substances and Their Alternatives for the Treatment of Pain was held in Boston on February 27, 2016, with a focus on MMJ for the treatment of chronic pain. Invited speakers had diverse backgrounds, including pain management, addiction psychiatry, neurology, and legal authorities. The purpose of this conference and this subsequent narrative review is to provide a medical, legal, and logistical framework for physicians and other health care providers to refer to when considering the initiation of medical marijuana therapy.

resultsThe invited speakers each covered a unique aspect of MMJ therapy for the treatment of chronic pain. These presentations highlighted the current data for and against the use of MMJ as a pain therapy. Optimal patient selection and screening, in addition to policy developments, were discussed.

conclusionsIncreasing interest in MMJ for chronic pain underscores a need for primary care and pain physicians to better understand the indications and evidence for its use free from cultural bias. Given a lack of full conclusive clinical utility, continued research is needed to better understand how to best utilize MMJ therapy for the treatment of chronic pain. Policy initiatives, such as enumerated indications, should follow medical science in order to prevent another abused substance epidemic.

Indexed as

CannabisAnalgesicsAnalgesics, OpioidChronic PainHumansMedical MarijuanaPain ManagementAnalgesicsAnalgesics, OpioidMedical MarijuanaAlternative TherapiesCannabisChronic PainNarcoticsPolicy

Identifiers

PMID29016917
PMCPMC7963205
OpenAlexW2735856559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.